跳至主要内容
临床试验/NCT00668473
NCT00668473已完成不适用

Endostatin and Other Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis

University of Michigan1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2007年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Level of endostatin in skin and serum

研究概览

简要总结

We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.

详细描述

Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis of the skin and internal organs. One of the earliest pathologic changes in patients with SSc is damage to the blood vessels. Many abnormalities have been found in the inner layer of the blood vessel, the enothelial tissue. It is known that there are mediators in the blood and tissues of the body that affect the endothelial tissue. These are called angiogenic (promote blood vessel formation) and angiostatic (inhibit blood vessel formation) mediators. Many of these mediators have been examined in the peripheral blood of patients with SSc, but fewer of these mediators have been examined at the site of action, in the tissue near the microvasculature. We hypothesize that there are differences in the levels of angiogenic/angiostatic mediators between healthy subjects and subjects with SSc. In addition, we propose that there are differences at skin sites that have varying levels of involvement with SSc of these angiogenic/angiostatic factors in subjects with SSc.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet American College of Rheumatology criteria for systemic sclerosis
  • Subjects with systemic sclerosis must have involvement proximal to the knee or elbow, excluding the face
  • Persons with no chronic health conditions

排除标准

  • Persons with systemic sclerosis as a result of being exposed to chemicals or drugs that can cause a sceroderma-like illness
  • Persons with autoimmune diseases other than systemic sclerosis
  • Persons treated with cyclophosphamide in the last 8 weeks
  • Persons with active infections, including but not limited to hepatitis C, hepatitis B, and HIV
  • Persons prone to bleeding because they are treated with medications that thin the blood or have a low platelet count

结局指标

主要结局

Level of endostatin in skin and serum

时间窗: At time of of biopsy and blood draw

次要结局

  • Level of JAM-A in skin and serum(At time of blood draw and skin biopsy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kristine Phillips

clinical assistant professor

University of Michigan

研究点 (1)

Loading locations...

相似试验